Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

Prior treatment

• 1\. Patient with atypical parkinsonism (such as suspected Progressive Supranuclear Palsy, Multiple System Atrophy) and secondary parkinsonism (such as normal pressure hydrocephalus, drug-induced, or vascular parkinsonism)
• 5\. History of exposure to typical or atypical neuroleptics or any dopamine blocking agent within 6 months prior to enrollment
• 14\. Participation in other investigational drug trials within 30 days prior to screening
• 15\. Contraindication for receiving MRI imaging such as presence of pacemakers, certain types of metallic implants, severe claustrophobia, history of reaction to contrast material, or renal insufficiency

Other illness

• 2\. Patients with uncertainty as to having classical Parkinson's disease, such as those who might have scans without evidence of dopaminergic deficits (SWEDDs)
• 3\. Presence of a medical or psychiatric comorbidity that can compromise participation in the study
• 7\. History of brain surgery for PD
• 8\. History of thyroid disease
• 9\. History of stroke or cerebral vascular disease
• 10\. History of drug abuse
• 11\. History of repeated head injury or encephalitis
• 12\. Positive dementia by DSM IV-R

Other

• 4\. Patients with clinically significant depression as determined by the Beck depression score \> 15
• 6\. Patients with psychosis/active hallucinations and memory difficulty pre-dating the onset of motor symptoms
• 13\. Women of childbearing potential who are not surgically sterilized have to use a reliable measure of contraception and have a negative urine pregnancy test at the screening

• 1\. Idiopathic Parkinson's Disease, REM Sleep Behavior Disorder subjects without signs of Parkinsonism and normal healthy controls a. If tremor is not present, subjects must have unilateral onset and persistent asymmetry of the symptoms. b. For PD Subjects only: Age \> 30 years at time of diagnosis of PD with a maximum age of 100 years old c. Hoehn \& Yahr stage \< V (if PD)
• 2\. For PD subjects only: Receiving an optimized dopaminergic regimen (i.e., either MAO-B inhibitor, a dopamine agonist and/or low doses of L-dopa, with dose change no more frequent than every 6-month in the course of the study); or medications naive
• 3\. No overt anemia, iron deficiency, or other hematological disorders
• 4\. Deemed healthy and able to undergo MRI and PE2i PET imaging by the Site Investigator, based on screening assessments-- medical history, physical examination 5. For Controls \& REM Sleep Behavior Disorder Subjects Only: Age 20-80; willing to undergo multiple imaging sessions 6. Signed informed consent form